<DOC>
	<DOC>NCT02819557</DOC>
	<brief_summary>This is a Phase 2, multiple-dose, open-label study evaluating the safety, and pharmacokinetics (PK) of ataluren in patients aged ≥2 to &lt;5 years old with Duchenne muscular dystrophy caused by a nonsense mutation in the dystrophin gene. The study includes a 4-week screening period, a 4-week study period, and a 48-week extension period for patients who complete the 4-week study period (52 weeks total treatment).</brief_summary>
	<brief_title>Study of Ataluren in ≥2 to &lt;5 Year-Old Males With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<criteria>Males ≥2 to &lt;5 years of age Body weight ≥12 kg Diagnosis of DMD Nonsense mutation in at least 1 allele of the dystrophin gene Participation in any other drug or device clinical investigation Ongoing use of prohibited concomitant medications</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>